| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378913 | Bioorganic & Medicinal Chemistry Letters | 2005 | 6 Pages |
Abstract
A novel series of nonnucleoside HCV NS5B polymerase inhibitors were prepared from (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid, a high throughput screening lead. SAR studies combined with structure based drug design focusing on the southern heterobiaryl region of the template led to the synthesis of several potent and orally bioavailable lead compounds. X-ray crystallography studies were also performed to understand the interaction of these inhibitors with HCV NS5B polymerase.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jeffrey A. Pfefferkorn, Meredith L. Greene, Richard A. Nugent, Rebecca J. Gross, Mark A. Mitchell, Barry C. Finzel, Melissa S. Harris, Peter A. Wells, John A. Shelly, Robert A. Anstadt, Robert E. Kilkuskie, Laurice A. Kopta, Francis J. Schwende,